Oncolytics Biotech Inc. 6-K Filing: February 2025 Insights & Updates

Based on the provided section of the financial report (6-K filing) for Oncolytics Biotech Inc., key information and insights include:

Basic Information:

• Document Type: Form 6-K
• Filing Date: February 19, 2025
• Commission File Number: 001-38512
• Company Name: Oncolytics Biotech Inc.
• Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5

Filings and Compliance:

• The filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
• The report is specifically for the month of February 2025.
• The registrant indicates that it files or will file annual reports under Form 20-F and Form 40-F.

Signature:

• The report is signed by Kirk Look, who is the Chief Financial Officer of Oncolytics Biotech Inc.
• The signature indicates that the report has been duly authorized by the company.

Attachments:

• Exhibit Number: 99.1
• Description: Press Release related to the company, which may contain important updates or announcements regarding operations, financial results, or other corporate news.

Regulatory Notes:

• The report references Regulation S-T Rules regarding the submission of paper documents, emphasizing compliance with SEC regulations for foreign private issuers.

Conclusion:

This document serves as an official communication to the SEC, detailing compliance with regulatory requirements and providing a basis for investors and analysts to assess Oncolytics Biotech Inc.’s activities and financial status as of February 2025. Further insights would likely be found in the attached press release, which could elaborate on recent developments or performance metrics.